Ligand's Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Press/Media: Press / Media

PeriodJun 20 2017

Media coverage

1

Media coverage

  • TitleLigand's Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    Media name/outletIndia Pharma News
    CountryIndia
    Date6/20/17
    PersonsJohn Andrew Higgins